Patents by Inventor Thomas Jozefiak

Thomas Jozefiak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11090354
    Abstract: The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: August 17, 2021
    Assignee: The Johns Hopkins University
    Inventors: Thomas Jozefiak, Michael Parlato, Pratik Patel, Kevin Colbert, Ashish Nimgaonkar, Pankaj Pasricha
  • Publication number: 20210213181
    Abstract: The present application relates to shear thinning hydrogel compositions which are useful for reducing and/or preventing tissue adhesion in a subject (e.g., a post-operative subject). Methods of using the compositions and kits comprising the compositions oar also provided.
    Type: Application
    Filed: May 29, 2019
    Publication date: July 15, 2021
    Inventors: Ali Khademhosseini, Guillermo Ulises Ruiz Esparza Herrera, Xichi Wang, Su Ryon Shin, Thomas Jozefiak
  • Publication number: 20180228863
    Abstract: The present invention provides compositions and methods for treatment of metabolic syndromes. Namely, the presently disclosed compositions and methods are provided for affecting the function of the gastrointestinal endocrine system in key regions of the gut, thereby, producing therapeutic effects on obesity, diabetes and other metabolic disorders. The compositions include components for forming luminal barriers within the gastrointestinal tract of a subject where the barrier is created in-situ via interaction of resident mucin with the mucin-interacting agent.
    Type: Application
    Filed: August 5, 2016
    Publication date: August 16, 2018
    Inventors: Thomas Jozefiak, Michael Parlato, Pratik Patel, Kevin Colbert, Ashish Nimgaonkar, Pankaj Pasricha
  • Publication number: 20070021509
    Abstract: Disclosed are compounds which have been identified as inhibitors of phosphate transport. Many of the compounds are represented by Structural Formula (I): Ar1—W—X—Y—Ar2; or a pharmaceutically acceptable salt thereof. Ar1 and Ar2 are independently a substituted or unsubstituted aryl group or an optionally substituted five membered or six membered non-aromatic heterocylic group fused to an optionally substituted monocylic aryl group. W and Y are independently a covalent bond or a C1-C3 substituted or unsubstituted alkylene group. X is a heteroatom-containing functional group, an aromatic heterocyclic group, substituted aromatic heterocyclic group, non-aromatic heterocyclic group, substituted non-aromatic heterocyclic group, an olefin group or a substituted olefin group. Also disclosed are methods of treating a subject with a disease associated with hyperphosphatemia, as well as a disease mediated by phosphate-transport function.
    Type: Application
    Filed: July 19, 2006
    Publication date: January 25, 2007
    Inventors: Thomas Jozefiak, Cecilia Bastos, Andrew Papoulis, Stephen Holmes-Farley
  • Publication number: 20060280719
    Abstract: Disclosed is a phosphate transport inhibiting compound represented by Structural Formula (I): R1 and R2 are independently —H, an electron withdrawing group or a C1-C10 alkyl group. Y is a covalent bond, a substituted methylene group, an unsubstituted methylene group or —CR1R2P(O)(OH)—. R3 is a hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a substituted hydrocarbyl group optionally comprising one or more amine, ammonium, ether, thioether or phenylene linking groups, a heteroaryl group, a substituted heteroaryl group or a phenyl group substituted with one or more groups selected from —Cl, —Br, —F, —CN, —NO2, —ORa, —N(Ra)2, —COORa, —CON(Ra)2, —CORa, —S(O)Ra, —S(O)2Ra, —S(O)2N(Ra)2, —NRaS(O)2Ra, —NRaCORa, a halogenated lower alkyl group, an aryl group, a substituted aryl group, or a halogenated alkoxy group. Each Ra is independently —H, lower alkyl, substituted lower alkyl, aryl or substituted aryl.
    Type: Application
    Filed: May 22, 2006
    Publication date: December 14, 2006
    Inventors: Thomas Jozefiak, Cecilia Bastos, Chad Huval
  • Patent number: 7048917
    Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: May 23, 2006
    Assignee: Genzyme Corporation
    Inventors: Thomas Jozefiak, Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Chad Cori Huval, Venkata R. Garigapati, Keith K. Shackett, Danny Concagh
  • Patent number: 6726906
    Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: April 27, 2004
    Assignee: Genzyme Corporation
    Inventors: Thomas Jozefiak, Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Chad Cori Huval, Venkata R. Garigapati, Keith K. Shackett, Danny Concagh
  • Patent number: 6299868
    Abstract: The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.
    Type: Grant
    Filed: July 14, 1999
    Date of Patent: October 9, 2001
    Assignee: GelTex Pharmaceuticals, Inc.
    Inventors: Thomas Jozefiak, Stephen Randall Holmes-Farley, W. Harry Mandeville, III, Chad Cori Huval, Venkata R. Garigapati, Keith K. Shackett, Danny Concagh